Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history

Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history


Pfizer has rejected allegations made by rival Moderna that its Covid-19 vaccine is a copy, accusing the Boston biotech company of rewriting history to lay claim to technology developed by a field of scientists over many years.

Pfizer asked a federal court in Massachusetts on Monday to dismiss Moderna’s lawsuit seeking monetary damages for alleged patent violations related to the Boston company’s Covid vaccine. Pfizer asked the court to stop Moderna from suing it or its partners again over three alleged patent infringements.

Moderna, in a complaint filed in August, accused Pfizer of copying two key pieces of technology that make the messenger RNA Covid vaccines possible.

Moderna accused Pfizer of using the same modification to mRNA that keeps the molecule stable long enough to program human cells to produce the crucial spike protein that triggers an immune response against Covid.

Moderna also accused Pfizer of using the same full-length spike protein in its Covid shots. Moderna says it demonstrated a full spike produced an immune response in 2015 when it developed an mRNA vaccine against the Middle East Respiratory Syndrome. That vaccine never went to market.

“The Moderna inventions that Pfizer and BioNTech chose to copy were foundational for the success of their vaccine,” the company claimed.

Pfizer and its German partner BioNTech vigorously rejected those allegations, saying the technological building blocks for the vaccines were developed by a field of research scientists before the pandemic began. They accused Moderna of trying to “place itself in the spotlight alone.”

“Moderna is wrong, and its revisionist history is not based on fact. Pfizer and BioNTech did not copy Moderna’s technology,” Pfizer said in its response. “Rather, Pfizer and BioNTech independently developed their vaccine by utilizing innovation from their respective scientists and relying upon decades of research conducted by others before the pandemic began.”

Pfizer said the modification to mRNA was developed by research scientists at the University of Pennsylvania, one of whom is now an executive at BioNTech. It rejected Moderna’s claim to own the full-length spike protein technology. Pfizer said scientists have worried about coronaviruses since the 2003 SARS outbreak and by 2009 scientists understood the full-length spike induced a strong immune response.

Pfizer and Moderna have generated tens of billions of dollars in revenue from the Covid vaccines and generated windfall profits since the shots were first authorized in December 2020.

Moderna is asking the court to award it monetary damages since March 2022 including royalties and lost profits with interest. The company is also seeking enhanced damages up to three times the amount of compensatory damages found.



Source

JPMorgan’s top biotech and pharma picks for the second half
Health

JPMorgan’s top biotech and pharma picks for the second half

Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. […]

Read More
How twin sister triathletes doubled down on sports success to raise health-startup millions from investors
Health

How twin sister triathletes doubled down on sports success to raise health-startup millions from investors

During their last year of completing work for doctoral degrees in physiology, twin sisters Michal Mor and Merav Mor started to compete in Ironman triathlon races. The demand for peak fitness led them to the realize the importance of understanding personal metabolism, and the lack of data being collected on it through devices accessible to […]

Read More
It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech
Health

It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech

Two graduate students research chemical products in a laboratory in Xiwangzhuang Town, Zaozhuang City, Shandong province of China, on Dec. 26, 2023. Nurphoto | Nurphoto | Getty Images BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China’s rapid rise in biotechnology, especially for drug and agricultural development. […]

Read More